AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00997191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Description: Intravitreal bevacizumab (1.5mg) associated to focal photocoagulation for diabetic macular edema at baseline; Re-treatment at weeks 20 and 40 if CMT>275um
Study NCT01327365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trans-radial PCI (TRI)
Description: TRI performed using the sheathless guiding approach
Study NCT00004184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alum adjuvant
Study NCT01579201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: First patient: 70 mcg. Following doses according to biased coin design up-down sequential allocation method, with increments or decrements of 10 mcg. An unsatisfactory uterine tone will lead to an increment while a satisfactory uterine tone will result in either a decrement or no change.
Study NCT00243893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minocycline
Description: Take minocycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
Study NCT01327365 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trans-radial PCI (TRI)
Description: TRI performed using a conventional guiding approach
Study NCT00243893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: Take doxycycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
Study NCT02551107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of nasal Nitric Oxide level
Description: ECO MEDICS CLD 88 sp Nitric Oxide Analyzer
Study NCT02551107 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of nasal Nitric Oxide level
Description: ECO MEDICS CLD 88 sp Nitric Oxide Analyzer
Study NCT03587103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protocol initiate with A
Description: The BP-lowering medication adjustment and titration will follow A-AC-ACD or A-AD-ADC for individuals randomized to A or two-drug combination therapy with full dose of A in their initial medication assignment.
Study NCT03587103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protocol initiate with C
Description: The BP-lowering medication adjustment and titration will follow C-CA-CAD or C-CD-CDA for individuals randomized to C or two-drug combination therapy with full dose of C in their initial medication assignment.
Study NCT03587103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protocol initiate with D
Description: The BP-lowering medication adjustment and titration will follow D-DA-DAC or D-DC-DCA for individuals randomized to D or two-drug combination therapy with full dose of D in their initial medication assignment.
Study NCT02912520 — intervention group
Intervention type: DRUG
Intervention: Anti-Bacterial Agents
Description: administration of any antibiotic substance(s) over the course of 2 weeks
Study NCT03095976 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amnion-Chorion allograft membrane on the root surface of periodontally diseased site.
Description: Application of Amnion-Chorion allograft membrane (ACM) on the root surface of periodontally diseased teeth in conjunction with corticocancellous allograft bone substitute covered by ACM in a combination GTR treatment of periodontal intrabony and furcation defects
Study NCT03180138 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminders alone
Description: Automated reminders (text and /or voice in local language) for upcoming vaccination visit(s) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.
Study NCT03180138 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Compliance-linked incentives
Description: Automated compliance-linked incentives (as cell-phone minutes) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.
Study NCT04576949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline
Description: film-coated oral tablets containing 3 mg cytisinicline
Study NCT04576949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: film-coated oral tablets containing matched placebo
Study NCT04576949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: film-coated oral tablets containing matched placebo
Study NCT04576949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral support
Description: Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.
Study NCT04576949 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral support
Description: Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.
Study NCT01066442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BF2.649 (Pitolisant)
Description: 1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
Study NCT02924402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb13676
Description: Biological
Study NCT02187081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation plus Sorafenib
Description: To treat HCC with the combination of radiofrequency ablation and sorafenib
Study NCT02187081 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: To treat HCC with radiofrequency ablation alone.
Study NCT01687205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Tenofovir Gel
Study NCT02113046 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreatico-jejunal anastomosis
Study NCT02113046 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional anastomosis
Study NCT00420407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline control
Description: no vasopressin added to bolus or 5 hour continuous infusion
Study NCT00420407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vasopressin
Description: vasopressin bolus 4 units followed by continuous infusion 2.4units/hr for 5 hours
Study NCT01849848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB L-0501
Description: The administration of SyB L-0501 at 90 mg/m\^2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.
Study NCT02584569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-915
Description: TAK-915 oral suspension
Study NCT02047123 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Raw Flaxseed
Description: The participants were randomly single blind controlled trial distributed into three groups: (1, n =30), (2, n =32), (3, n =27). For 30 days, participants in group 1 took with 15g flaxseed mixed with yoghurt and diet,(the 15g of flaxseed that was provided in addition to the linen package spoon so all would take far it) group 2 took yoghurt and diet, and group 3 only received the diet.
Study NCT02725385 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02725385 — intervention group
Intervention type: OTHER
Intervention: Physiologic Testing
Description: Undergo Trier Social Stress Test
Study NCT02725385 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study NCT03384511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Patients will accept apatinib therapy and undergo baseline 18F-ALF-NOTA-PRGD2 PET/CT scans of the whole body after having met all eligibility criterias.
Study NCT02562196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tdcs
Description: The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds.
Study NCT02562196 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tdcs
Description: The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds.
Study NCT03396471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg IV at day -21, then day 1 of each 21-day cycle for a maximum of 24 continuous months of Pembrolizumab (35 cycles) from Cycle 1 Day 1 (C1D1) can be administered.
Study NCT03396471 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: 20-30 Gy over five fractions for up to two cycles.
Study NCT00200148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normovolemic Hemodilution (ANH)
Description: For those patients randomized to ANH, the pre-calculated volume of blood will be withdrawn to a target hemoglobin of 8.0 - 8.5 g/dl (maximum of 3 L) using the formula VL=EBV x (HO-HF)/Hav, as above. The removed blood will be stored in a standard citrate-phosphate-dextrose buffer solution in blood storage bags in the operating room. During removal of blood, colloid and crystalloid solutions will be administered via peripheral intravenous lines in order to maintain euvolemia. For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.For patients randomized to ANH, autologous blood will be re-infused in the reverse order from which it was removed, and allogeneic blood will given only after all autologous blood has been given.
Study NCT00200148 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: An 8.5 French central venous catheter and an arterial line will be placed in all patients. If the patient has a central line already in place, this may be used in place of the 8.5 French internal jugular catheter. Continuous monitoring of heart rate, blood pressure, ECG (II, V5), CVP, end tidal CO2, oxygen saturation, temperature and urine output will be performed for all patients.For all hepatic resections, standard low CVP anesthetic management will be employed.For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.All patients will receive standard postoperative management. Routine laboratory studies, including comprehensive panel, CBC and coagulation profile, will be obtained daily in the post-operative period.
Study NCT02777840 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: face mask oxygen
Description: oxygen given by face mask as per routine practice
Study NCT02777840 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow oxygen
Description: High flow oxygen given via optiflo machine / device
Study NCT04143880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: intramuscular injection intranasal administration
Study NCT04143880 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: intramuscular injection intranasal administration
Study NCT03028545 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Collection of the individual narrative, semi-directed interviews
Description: Visit one : individual interview Individual narrative Passing Psychometric Measurement Scales of Recovery: Score at Warwick and Wellness Scale Andreasen scale score Visit two Focus group
Study NCT01258270 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postop Dressing
Description: The AQUACEL® Ag Surgical Dressing is a silver impregnated, waterproof, adhesive dressing that sticks to the skin around the wound and blocks bacteria from the outside.
Study NCT01258270 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postop Dressing
Description: A standard island dressing consists of adhesive tape and gauze.
Study NCT03762538 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Patients will be induced to unconsciousness using propofol intravenously.
Study NCT02690402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: adapted physical activity
Description: The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
Study NCT04344288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: The experimental group will receive oral prednisone during 10 days (0.75 mg/kg/day during 5 days then 20 mg/day during 5 more days)
Study NCT04344288 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The control group will receive standard of care according to the international recommendations and practices of the investigational site. No corticosteroid therapy can be prescribed in this group.
Study NCT01837771 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragmatic stimulation
Study NCT03583203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: personalized information about lung damage
Description: Chronic obstructive pulmonary disease (COPD) will be evaluated using spirometry. Based on this value, a motivational message about prevention will be issued for the intervention group, which will be reinforced by individualized text messages over a period of 3 months
Study NCT04188626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Driving simulator sessions
Description: The volunteers will be placed in a driving simulator that will simulate autonomous highway driving. This autonomous driving will be interrupted by take-over requests related to events that disrupt autonomous driving. During autonomous driving, the driver will have to disengage from driving by performing non-related driving tasks. During each non-related driving tasks, a take-over request will be sent. Electrophysiological (EEG, ECG, EDA, EMG, respiration) and behavioural data will be recorded before, during and after the take-over control.
Study NCT04195477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vDPP
Description: virtual Diabetes Prevention Program
Study NCT04079374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Subcutaneous injections
Study NCT04079374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enbrel
Description: Subcutaneous injections
Study NCT00280293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine
Study NCT00280293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03072082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danlou Tablet
Description: Conventional western medicine \& Danlou Tablet
Study NCT03072082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DanLou Tablet placebo
Description: Conventional western medicine \& placebo (for Danlou Tablet)
Study NCT03072082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Enteric-coated Tablets
Description: 100 mg tablet, one tablet daily.
Study NCT02563873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tailored pacemaker settings
Description: Tailored pacemaker settings, optimised for cardiac contractility: Pacemaker settings, optimised for cardiac contractility as determined by echocardiography, will be programmed
Study NCT05000606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A home visit program
Description: A home visit program including education and counseling was applied. A total of five home visits over three months were performed.
Study NCT01652677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation is a noninvasive technique for including electrical currents in the cerebral cortex by means of time-varying magnetic fields.
Study NCT03072082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin Enteric-coated Tablets
Description: 100 mg tablet, one tablet daily.
Study NCT03072082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
Description: One tablet daily. (for patients who can't use aspirin)
Study NCT01652677 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation is a noninvasive technique for including electrical currents in the cerebral cortex by means of time-varying magnetic fields.
Study NCT02501863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femoral nerve block with ropivacaine+fentanyl
Description: Ropivacaine+fentanyl are used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
Study NCT01355991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: 18mcg/ capsule inhaled once daily for two weeks.
Study NCT01355991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: 50mcg inhalation twice daily for two weeks
Study NCT04283461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.
Study NCT02501863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femoral nerve block with ropivacaine
Description: Ropivacaine is used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
Study NCT03237312 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic ovarian drilling
Description: The electric current used was set at 40 Watts. The power was activated just before touching the ovary, and then the needle electrode was held against the antimesenteric surface of the ovary for 4 seconds until penetration of the ovarian capsule. Four or eight puncture points were made through the ovarian capsule of each ovary according to the study protocol. The ovaries were cooled in the pool of the Ringer's lactate after each cauterization both to minimize adhesion formation and to prevent heat trauma to the adjacent viscera. Complete hemostasis was ensured. At the end of the procedure, the ovaries were copiously rinsed with Ringer's lactate (Aqua-purator, Storz, Germany). An amount about 200 ml of heparinized Ringers lactate (5000 IU/1000 ml) was left in the pelvis to avoid postoperative adhesions.
Study NCT03072082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
Description: One tablet daily. (for patients who can't use aspirin)
Study NCT03072082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin calcium
Description: 10 mg tablet, two tablets each night.
Study NCT03072082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin calcium
Description: 10 mg tablet, two tablets each night.
Study NCT03237312 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Antimullerian hormone
Description: 1. In patients with Antimullerian hormone between 4-8 ng/ml 4 punctures in each ovary were performed.~2. In patients with Antimullerian hormone above 8 ng/ml 8 punctures in each ovary were performed.
Study NCT03072082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate Tab 20 MG
Description: One tablet two times daily.
Study NCT03072082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isosorbide Mononitrate Tab 20 MG
Description: One tablet two times daily.